Lupin advances on tie up with Abbvie

Shares of the pharma major Lupin Limited rose as much as 2.10 percent to Rs 875.45 after the company announced partnership with Abbvie for developing and commercializing novel oncology drug to treat Hematological Cancers.

With this partnership, Abbvie gains exclusive global rights to develop and commercialize Lupin's MALT1 inhibitors.

MALT-1 is a protein involved in T-cell and B-cell lymphocyte activation. AbbVie intends to pursue development across a range of hematological cancers, many with limited current treatment options.

Source : Equity Bulls

Keywords